UNSPSC 51342701: Atazanavir

This classification denotes a protease inhibitor with the molecular formula C38H52N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZU4H47A3S, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)- but generally known as atazanavir, which bears US NIH Compound Identifier 148192. Atazanavir most often comes in base and sulfate forms.

UNSPSC 51342701 Atazanavir, a Commodity-tier code, nominally covers the antiretroviral pharmaceutical atazanavir; however, recent state and local procurement activity under this code shows little alignment with that specific product. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities tagged to this code, but the actual goods being solicited—Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets in one case, Naloxone and Safe Drug Deactivation Systems in the other—fall outside atazanavir's therapeutic scope. The mismatch suggests potential misclassification or broader pharmaceutical procurement grouping by issuing bodies. When pharmaceutical commodities are correctly coded, state and local health departments and county community health programs are the primary buyers, typically seeking pharmaceuticals through cooperative purchasing vehicles (such as MMCAP Infuse) or competitive sealed bidding for specific quantities and delivery schedules.

Activity is geographically limited to Illinois and Florida in recent records. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC (Bid Number 26-482DPH-PREPDB53392, completed in August 2026) for $2,999,999.11 over the full contract term including renewals, with 12-month initial term and two renewal options. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS) on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though the due date listed (July 26, 2023) appears to be a data error. Neither opportunity explicitly specifies set-asides or preference programs. The code shows minimal recent activity, and the product mismatches across posted opportunities suggest checking downstream commodity codes for better alignment before committing resources to pursue atazanavir-specific opportunities.